Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Alto Neuroscience , Inc. (NYSE:ANRO), a pharmaceutical company currently trading at $4.18 per share, has entered into a Sales Agreement with Leerink Partners LLC, initiating an "at the market" ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating ... Earlier this month, Ecor1 Capital, Llc, a Director at ANAB bought 85,098.00 shares for a ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partn ...

Align Technology upgraded to Outperform with a $280 price target by Leerink Partners. Q3 adjusted EPS beats at $2.35, while sales rose 1.8% to $977.9 million. Get the Real Story Behind Every Major ...